BACKGROUND: Some patients with autoimmune characteristics and idiopathic interstitial pneumonia, particularly usual interstitial pneumonia (UIP), do not fit neatly into the category of connective tissue disease-associated interstitial lung disease (CTD-ILD), idiopathic pulmonary fibrosis (IPF), or recently proposed yet to be validated criteria for interstitial pneumonia with autoimmune features (IPAF). Outcomes of these patients are unknown. METHODS: This was a retrospective single-center study. Analyses of variance compared differences in mean change in FVC and diffusion capacity (Dlco) over 1 year among 124 well-defined patients (20 patients with positive autoantibodies with or without symptoms of connective tissue disease [AI-ILD], 15 patients with IPAF, 36 patients with CTD-ILD, and 53 patients with IPF with negative CTD serologies [Lone-IPF]). RESULTS: Of the patients, 75% with AI-ILD, 33% with IPAF, and 33% with CTD-ILD had UIP. Initial FVC and Dlco were similarly moderately reduced across groups. Mean change in FVC over 12 months was as follows: -60 mL (IPAF), -110 mL (AI-ILD), -10 mL (CTD-ILD), and -90 mL (Lone-IPF) (P = .52). Mean change in Dlco was as follows: 2.39 mL/mm Hg/min (IPAF), -1.15 mL/mm Hg/min (AI-ILD), -0.27 mL/mm Hg/min (CTD-ILD), and -1.05 mL/mm Hg/min (Lone-IPF) (P < .001). By pattern of disease, the mean change in FVC was as follows: -140 mL (UIP), 10 mL (nonspecific interstitial pneumonia), and 12 mL (unclassifiable/other) (P = .001). CONCLUSIONS: No clinically significant differences in pulmonary function to distinguish between patients with AI-ILD, IPAF, CTD-ILD, and Lone-IPF were observed after 1 year. Longer periods of follow-up are needed to understand the outcomes of these patients. It is not yet clear whether AI-ILD is a distinct phenotype or a variant of the newly proposed entity IPAF.
BACKGROUND: Some patients with autoimmune characteristics and idiopathic interstitial pneumonia, particularly usual interstitial pneumonia (UIP), do not fit neatly into the category of connective tissue disease-associated interstitial lung disease (CTD-ILD), idiopathic pulmonary fibrosis (IPF), or recently proposed yet to be validated criteria for interstitial pneumonia with autoimmune features (IPAF). Outcomes of these patients are unknown. METHODS: This was a retrospective single-center study. Analyses of variance compared differences in mean change in FVC and diffusion capacity (Dlco) over 1 year among 124 well-defined patients (20 patients with positive autoantibodies with or without symptoms of connective tissue disease [AI-ILD], 15 patients with IPAF, 36 patients with CTD-ILD, and 53 patients with IPF with negative CTD serologies [Lone-IPF]). RESULTS: Of the patients, 75% with AI-ILD, 33% with IPAF, and 33% with CTD-ILD had UIP. Initial FVC and Dlco were similarly moderately reduced across groups. Mean change in FVC over 12 months was as follows: -60 mL (IPAF), -110 mL (AI-ILD), -10 mL (CTD-ILD), and -90 mL (Lone-IPF) (P = .52). Mean change in Dlco was as follows: 2.39 mL/mm Hg/min (IPAF), -1.15 mL/mm Hg/min (AI-ILD), -0.27 mL/mm Hg/min (CTD-ILD), and -1.05 mL/mm Hg/min (Lone-IPF) (P < .001). By pattern of disease, the mean change in FVC was as follows: -140 mL (UIP), 10 mL (nonspecific interstitial pneumonia), and 12 mL (unclassifiable/other) (P = .001). CONCLUSIONS: No clinically significant differences in pulmonary function to distinguish between patients with AI-ILD, IPAF, CTD-ILD, and Lone-IPF were observed after 1 year. Longer periods of follow-up are needed to understand the outcomes of these patients. It is not yet clear whether AI-ILD is a distinct phenotype or a variant of the newly proposed entity IPAF.
Authors: Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Ho-Cheol Kim; Wonjun Ji; Mi Young Kim; Thomas V Colby; Se Jin Jang; Chang-Keun Lee; Seung Bong Han; Dong Soon Kim Journal: Chest Date: 2015-01 Impact factor: 9.410
Authors: M N Manoussakis; A G Tzioufas; M P Silis; P J Pange; J Goudevenos; H M Moutsopoulos Journal: Clin Exp Immunol Date: 1987-09 Impact factor: 4.330
Authors: Yang Hu; Liu-Sheng Wang; Ya-Ru Wei; Shan-Shan Du; Yu-Kui Du; Xian He; Nan Li; Ying Zhou; Qiu-Hong Li; Yi-Liang Su; Fen Zhang; Li Shen; Dong Weng; Kevin K Brown; Hui-Ping Li Journal: Chest Date: 2016-01-06 Impact factor: 9.410
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Joyce S Lee; Eunice J Kim; Kara L Lynch; Brett Elicker; Christopher J Ryerson; Tamiko R Katsumoto; Anthony K Shum; Paul J Wolters; Stefania Cerri; Luca Richeldi; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Respir Med Date: 2012-11-24 Impact factor: 3.415
Authors: Joshua J Solomon; Jonathan H Chung; Gregory P Cosgrove; M Kristen Demoruelle; Evans R Fernandez-Perez; Aryeh Fischer; Stephen K Frankel; Stephen B Hobbs; Tristan J Huie; Jill Ketzer; Amar Mannina; Amy L Olson; Gloria Russell; Yutaka Tsuchiya; Zulma X Yunt; Pearlanne T Zelarney; Kevin K Brown; Jeffrey J Swigris Journal: Eur Respir J Date: 2015-11-19 Impact factor: 16.671
Authors: Ayodeji Adegunsoye; Justin M Oldham; Catherine Bonham; Cara Hrusch; Paul Nolan; Wesley Klejch; Shashi Bellam; Uday Mehta; Kiran Thakrar; Janelle Vu Pugashetti; Aliya N Husain; Steven M Montner; Christopher M Straus; Rekha Vij; Anne I Sperling; Imre Noth; Mary E Strek; Jonathan H Chung Journal: Am J Respir Crit Care Med Date: 2019-03-15 Impact factor: 21.405
Authors: Ho Cheol Kim; Joon Seon Song; Sojung Park; Hee-Young Yoon; So Yun Lim; Eun Jin Chae; Se Jin Jang; Jin Woo Song Journal: Sci Rep Date: 2020-12-03 Impact factor: 4.379